Munich’s mbiomics closes €30M to develop live bacterial product
Summary
mbiomics completes a €30M Series A to advance MBX-116, a live bacterial product designed to improve immune checkpoint inhibitor response in advanced melanoma.
Description
mbiomics completes a €30M Series A to advance MBX-116, a live bacterial product designed to improve immune checkpoint inhibitor response in advanced melanoma.
Original reporting
AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.
Open original source